Cancer Research and Treatment

Original Articles

Association between Metformin Use and Survival in Nonmetastatic Rectal Cancer Treated with a Curative Resection: A Nationwide Population Study: Young-Jun Ki, Hyo Jeong Kim, Mi-Sook Kim, Chan Mi Park, Min Jung Ko, Young Seok Seo, Sun Mi Moon, Jin A Choi; Cancer Res Treat. 2017;49(1):29-36. Published online July 4, 2016; DOI: https://doi.org/10.4143/crt.2016.128

Purpose
Metformin is associated with an anticancer effect. However, the effects of metformin in rectal cancer are controversial. This study investigated the impact of metformin on the survival of patients with diabetes mellitus and nonmetastatic rectal cancer who underwent curative surgery.
Materials and Methods
The database was provided by the Korea Center Cancer Registry and National Health Insurance Service of the Republic of Korea. A cohort of patients with newly diagnosed rectal cancer between 2005 and 2011 was identified. Drug exposure was defined as receiving the oral hypoglycemic agent for at least 90 days over the period from 6 months before the initial diagnosis of rectal cancer to the last follow-up.
Results
A total of 4,503 patients were prescribed oral hypoglycemic agents and classified as the diabetic group, of which 3,694 patients received metformin for at least 90 days. Unadjusted analyses showed a significantly higher overall survival (hazard ratio, 0.596; 95% confidence interval, 0.506 to 0.702) and rectal cancer-specific survival (hazard ratio, 0.621; 95% confidence interval, 0.507 to 0.760) in the metformin group than in the nonmetformin group. The adjusted overall survival (hazard ratio, 0.631; 95% confidence interval, 0.527 to 0.755) and cancer-specific survival (hazard ratio, 0.598; 95% confidence interval, 0.479 to 0.746) in the group with a medication possession ratio of 80% or greater was significantly higher than in the group with a medication possession ratio of less than 80%.
Conclusion
Metformin use is associated with overall and cancer-specific survival in diabetic patients with a nonmetastatic rectal cancer treated with a curative resection.

Citations

Citations to this article as recorded by

Metformin Does not Affect Outcomes in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Therapy and Resection
Swati Sonal, Chloe Boudreau, Hiroko Kunitake, Robert N. Goldstone, Grace C. Lee, Christy E. Cauley, Liliana G. Bordeianou, Todd D. Francone, Rocco Ricciardi, David L. Berger
The American Surgeon™.2024; 90(4): 858. CrossRef
View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences
Guglielmina Froldi
Pharmaceuticals.2024; 17(4): 478. CrossRef
Type II diabetes and metformin use does not affect colorectal cancer prognosis
Mehrnoosh Shahrivar, Caroline E. Dietrich, Bengt Glimelius, Deborah Saraste, Anna Martling, Christian Buchli, Caroline Nordenvall
International Journal of Cancer.2024;[Epub] CrossRef
Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome
Ji Soo Park, Soo Jin Moon, Hyung Seok Park, Sang-Hoon Cho
Preventive Medicine Reports.2024; 48: 102928. CrossRef
Metformin combined with local irradiation provokes abscopal effects in a murine rectal cancer model
Mineyuki Tojo, Hideyo Miyato, Koji Koinuma, Hisanaga Horie, Hidenori Tsukui, Yuki Kimura, Yuki Kaneko, Hideyuki Ohzawa, Hironori Yamaguchi, Kotaro Yoshimura, Alan Kawarai Lefor, Naohiro Sata, Joji Kitayama
Scientific Reports.2022;[Epub] CrossRef
Clinicopathological Characteristics and Overall 5-Year Survival of Colorectal Cancer: A Retrospective Study
Rahaf Almuhanna, Fatma Al-Thoubaity, Khadijah Almalki, Nada Algarni, Renad Hamad, Toleen Makhtoum
Medical Sciences.2022; 10(3): 42. CrossRef
Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
Jing Yang, Hang Yang, Ling Cao, Yuzhen Yin, Ying Shen, Wei Zhu
Medicine.2022; 101(49): e31799. CrossRef
Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study
Byoung Hyuck Kim, Moon-June Cho, Jeanny Kwon
International Journal of Clinical Oncology.2021; 26(11): 2004. CrossRef
Suppressive effects of metformin on colorectal adenoma incidence and malignant progression
Min Deng, Siqin Lei, Dongdong Huang, Hui Wang, Shuli Xia, Enping Xu, Yihua Wu, Honghe Zhang
Pathology - Research and Practice.2020; 216(2): 152775. CrossRef
Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences
Yunzi Wang, Jingping Xiao, Yuanyu Zhao, Shijuan Du, Jiang Du
International Journal of Colorectal Disease.2020; 35(5): 827. CrossRef
Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study
Wen‐Kuan Huang, Shu‐Hao Chang, Hung‐Chih Hsu, Wen‐Chi Chou, Tsai‐Sheng Yang, Jen‐Shi Chen, John Wen‐Cheng Chang, Yung‐Chang Lin, Chang‐Fu Kuo, Lai‐Chu See
International Journal of Cancer.2020; 147(7): 1904. CrossRef
Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression
Cheng-Ann Winston Ng, Amy Aimei Jiang, Emma Min Shuen Toh, Cheng Han Ng, Zhi Hao Ong, Siyu Peng, Hui Yu Tham, Raghav Sundar, Choon Seng Chong, Chin Meng Khoo
International Journal of Colorectal Disease.2020; 35(8): 1501. CrossRef
Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus
Akira Saito, Joji Kitayama, Hisanaga Horie, Koji Koinuma, Hideyuki Ohzawa, Hironori Yamaguchi, Hiroshi Kawahira, Toshiki Mimura, Alan Kawarai Lefor, Naohiro Sata
Cancer Science.2020; 111(11): 4012. CrossRef
Patterns of Rectal Cancer Radiotherapy Adopting Evidence-Based Medicine: An Analysis of the National Database from 2005 to 2016
Hae Jin Park, Sanghyun Cho, Yoon Kim
Cancer Research and Treatment.2018; 50(3): 975. CrossRef
UEG Week 2018 Poster Presentations

United European Gastroenterology Journal.2018;[Epub] CrossRef

11,812 View
307 Download
17 Web of Science
15 Crossref

Immunogenicity of Influenza Vaccine in Colorectal Cancer Patients: Dong Ho Kim, Yun Yong Lee, Ui Sup Shin, Sun Mi Moon; Cancer Res Treat. 2013;45(4):303-312. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.303

Abstract PDF PubReader ePub

PURPOSE
Although influenza is regarded as a major cause of morbidity and mortality in immunocompromised patients, vaccine coverage remains poor. We evaluated the immunogenicity of influenza vaccines in colorectal cancer patients.
MATERIALS AND METHODS
In this study, 40 colorectal cancer patients who received an influenza vaccine at the Korea Cancer Center Hospital during the 2009-2010 and 2010-2011 influenza seasons were analyzed. The blood samples were collected at prevaccination and 30 days post vaccination, and antibody titers were measured using the hemagglutination-inhibition tests.
RESULTS
In the 2009-2011 season, the seroprotection rate for H1N1 (94.7%) was significantly higher than that for H3N2 (42.1%) and B (47.3%). The seroconversion rate was 52.6%, 26.3%, and 36.8% for H1N1, H3N2, and B, respectively. Fold increase of geometric mean titer (MFI) was 3.86, 1.49, and 3.33 for H1N1, H3N2, and B, respectively. In the 2010-2011 season, the seroprotection rate for H1N1 (57.1%) was significantly higher than that for H3N2 (52.4%) and B (38.1%). The seroconversion rate was 52.4%, 47.6% and 33.3% for H1N1, H3N2, and B, respectively. MFI was 12.29, 3.62 and 4.27 for H1N1, H3N2, and B, respectively.
CONCLUSION
Our study cohort showed an acceptable immune response to an influenza vaccine without significant adverse effects, supporting the recommendation for annual influenza vaccination in colorectal cancer patients.

Citations

Citations to this article as recorded by

Therapeutic vaccines for colorectal cancer: The progress and future prospect
Mina Shahnazari, Pouria Samadi, Mona Pourjafar, Akram Jalali
International Immunopharmacology.2020; 88: 106944. CrossRef
Vaccines for colorectal cancer: an update
Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh
Journal of Cellular Biochemistry.2019; 120(6): 8815. CrossRef
Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season
Maria Ganczak, Paulina Dubiel, Marzena Drozd-Dąbrowska, Ewelina Hallmann-Szelińska, Karol Szymański, Lidia B. Brydak
International Journal of Environmental Research and Public Health.2019; 16(22): 4489. CrossRef
Immunogenicity of Influenza Vaccination in Patients With Cancer
Saiama N. Waqar, Leigh Boehmer, Daniel Morgensztern, Andrea Wang-Gillam, Steven Sorscher, Steven Lawrence, Feng Gao, Kalin Guebert, Kristina Williams, Ramaswamy Govindan
American Journal of Clinical Oncology.2018; 41(3): 248. CrossRef
Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy
Kei Nakashima, Masahiro Aoshima, Satoko Ohfuji, Kanzo Suzuki, Masahiro Katsurada, Naoko Katsurada, Masafumi Misawa, Yoshihito Otsuka, Kyoko Kondo, Yoshio Hirota
Human Vaccines & Immunotherapeutics.2017; 13(3): 543. CrossRef
Influenza vaccination in adult patients with solid tumours treated with chemotherapy
Albert Vollaard, Imke Schreuder, Lizzy Slok-Raijmakers, Wim Opstelten, Guus Rimmelzwaan, Hans Gelderblom
European Journal of Cancer.2017; 76: 134. CrossRef
Vaccination in Patients with Primary Immune Deficiency, Secondary Immune Deficiency and Autoimmunity with Immune Regulatory Abnormalities
Martha M Eibl, Hermann M Wolf
Immunotherapy.2015; 7(12): 1273. CrossRef

44,737 View
59 Download
7 Crossref

First
Prev
Page of 1
Next
Last

Search